HHTM

MIAMI, FLORIDA — ELEHEAR, the AI hearing technology company, today announced the launch of ElePro Plus, a live tele-audiology service that gives users one-on-one access to licensed professionals remotely, on their own schedule, through the ELEHEAR app. The service became available August 17 and builds on the company’s existing ElePro Basic remote fitting service. ElePro Plus is initially available for

GN’s new ReSound Sensia hearing aids build on the AI and Deep Neural Network (DNN) technology introduced with ReSound Vivia, with a major change: advanced speech-in-noise processing can now engage automatically. At the center of the new platform is AcoustIQ™, which analyzes the listening environment and determines when to activate directional processing, DNN-based noise reduction, and other features to support

Jabra Enhance has launched its next-generation M Series, a new lineup of three FDA-cleared self-fitting hearing aids: the Enhance Select M3, M2, and M1. The flagship Enhance Select M3 is described by the company as the world’s smallest rechargeable micro receiver-in-ear (RIE) hearing aid and introduces Jabra Enhance’s latest speech and noise-management features. New SoundScape Speech Technology The Enhance Select

BLUFFDALE, UTAH & NEWARK-ON-TRENT, U.K. — Vue has deployed an Auracast-based assistive listening system across 20 cinemas in the United Kingdom and Ireland, bringing direct wireless audio access to more than 200 screens. The installation uses Auri, an assistive listening system developed by Listen Technologies and Ampetronic around Bluetooth Auracast broadcast audio. According to the companies, the participating Vue locations

Fennec Pharmaceuticals reported continued growth in demand for PEDMARK® (sodium thiosulfate), its treatment designed to reduce the risk of hearing loss associated with cisplatin chemotherapy, as new clinical evidence adds support for protecting hearing without compromising cisplatin’s antitumor activity. PEDMARK net product sales reached $17.1 million during the second quarter of 2026, up 78% from $9.7 million during the same

Toronto audiologist Emilie Vos, AuD, placed second runner-up at Miss Universe Canada 2026, using the national competition to bring greater attention to hearing healthcare, newborn hearing screening and hearing conservation. Vos finished among the top three delegates in the competition and was also named a Top Five Humanitarian finalist and finished among the Top Three in the People’s Choice vote.

Oticon has introduced Oticon Reveal™, a new hearing aid platform featuring what the company describes as the world’s first Dual AI system for hearing aids. The new platform uses two dedicated AI systems—one focused on speech and another on contextual sounds—with the goal of providing clearer speech while preserving meaningful sounds in the surrounding environment. Oticon Reveal also incorporates a

Samsung Electronics announced that its Galaxy Buds Hearing Aid feature has received clearance from the U.S. Food and Drug Administration (FDA), allowing compatible Galaxy Buds1 to function as over-the-counter (OTC) hearing aids2 for adults age 18 and older with perceived mild to moderate hearing loss. The feature is designed for users who may have difficulty following conversations in noisy environments

Accessible communication technology is advancing rapidly, but building tools that people can truly depend on requires more than simply adding artificial intelligence. Brian Taylor speaks with InnoCaption CEO Paul Lee about the evolution of captioned communication, the company’s milestone of supporting more than 30 million captioned calls, and the importance of keeping users at the center of accessibility technology. Lee

CAMBRIDGE, MASSACHUSSETTS — Skylark Bio, a clinical-stage biotechnology company developing targeted genetic medicines for hearing loss and other monogenic disorders, announced that the first patient has been dosed in the SONIX Phase 1/2 clinical trial evaluating SKY-GJB2, the company’s investigational inner-ear-targeted gene therapy for GJB2-mediated hearing loss. “Dosing the first patient in SONIX brings us one step closer to a future